The Opportunity: What 5+5, the Ceiling List and Contract Manufacturing Opened Up

Nigerian manufacturing stories usually run on hope. This one runs on policy that’s already been implemented and numbers that have already moved.

Two instruments did most of the work, and neither is new.

The 5+5 policy

Introduced by NAFDAC in 2019, it phases out imports of medicines that Nigerian manufacturers can produce locally. Products selected through scientific survey become prohibited from importation. Companies that want to keep selling them either build a facility here or contract a qualified Nigerian manufacturer.

That’s a demand transfer, not a subsidy. Somebody was already selling those products. Now that volume has to be made in Nigeria.

The Ceiling List

The same idea, applied product by product. Nine products were restricted from importation in 2020. By 2026 the list had grown to 36.

It’s still expanding, which is the interesting part for anyone planning. A product on the list next year is a product whose importers need a local manufacturing answer next year.

What the two of them did

NAFDAC reported in September 2026 that imports of the affected medicines had fallen by 70 per cent, and the share of locally manufactured pharmaceutical products had risen from 30 per cent to 50 per cent.

Company numbers moved with it. Pharmaceutical manufacturers went from 174 to 190. By June 2026, 176 companies had been through NAFDAC facility layout review and approval, and 106 of those were new companies rather than existing manufacturers expanding. The agency counted 28 newly developed or retrofitted companies and 16 new facilities, adding up to roughly a 25 per cent increase in local manufacturing.

PVAC says at least eleven pharmaceutical manufacturing projects are due for commissioning during 2026. And four pharmaceutical companies finished among the ten best performing firms on the Nigerian Exchange in 2025, on a list that used to belong to banks and oil companies.

The market underneath

Nigeria has been importing roughly 70 per cent of its pharmaceutical requirement. Government policy targets 70 per cent local production by 2030, which is the same number pointed the other way.

Coherent Market Insights values the domestic pharmaceutical market at 3.34 billion dollars in 2026 with around 9.5 per cent annual growth projected through 2033. Treat that figure with caution, because estimates for this market vary widely depending on what’s counted. The direction is better evidence than the decimal places.

Regionally, Nigeria already accounts for about 60 per cent of drug manufacturing in ECOWAS. PVAC’s stated ambitions include doubling Nigeria’s share of the African pharmaceutical market to at least 15 per cent. Export is a genuine part of this, not decoration.

Contract manufacturing, the part most people miss

The sharpest number in the whole set. Companies engaged in contract manufacturing in Nigeria rose from 10 in 2019 to 87 in 2026.

That growth cuts two ways, and both are opportunities.

If you own a brand and no factory, you can register your product, own the trademark, and have it manufactured in someone else’s licensed, inspected plant. You avoid the press, the HVAC, the purified water system, the superintendent pharmacist on payroll and the GMP inspection. You give up margin and you depend on someone else’s quality system. For a first product, that trade is usually worth making. Get out of the equipment question entirely until you’ve proved the product sells.

If you own a plant with spare capacity, you have a second business. NAFDAC has framed the contract manufacturing growth as companies making better use of existing capacity. A press running four days a week can run six, and toll manufacturing pays for that without you registering a single new product of your own.

This is where the oversized press argument softens. A machine bought too big for your own products isn’t dead capital if you can fill it with contract work. But you need the contracts before you buy, not afterwards.

Where the gaps look real

Nigeria still imports nearly all of its active pharmaceutical ingredients, excipients and packaging. The Executive Order gave those inputs relief precisely because there’s no local supply to protect. Anyone with a serious chemical manufacturing background should be looking upstream, not at another tablet line.

Retrofitting is another one. NAFDAC noted existing facilities being upgraded to meet current GMP standards. That’s engineering, HVAC, water systems, validation consultancy and equipment replacement, and it’s a services market attached to the manufacturing wave rather than competing in it.

The honest caveat

Import restriction creates demand. It does not create a customer for you specifically. The existing 190 manufacturers are not standing still, and several of them have decades of distribution relationships, registered product portfolios and balance sheets you can’t match.

Ask which specific product, on which list, that you can register and distribute. If you can’t name it, the policy environment is interesting but it isn’t yet a business.

Figures here come from NAFDAC, PVAC and Federal Ministry of Health statements reported through September 2026.